The cover image is based on the accelerated article CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19: A potential link to molecular pathophysiology? by Justyna Siwy et al., 10.1002/pmic.202100133, and the accelerated article SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing by Agnieszka Latosinska et al., 10.1002/pmic.202100160.

Now the circle of our investigations in the area of COVID-19 is complete: starting with (early) detection and prediction (CoV50 test), through clarification of the molecular pathophysiology (CD99 and PIGR reduction, endothelial damage), up to the prediction of potentially effective drugs (SGLT2 Inhibitors).

This was only possible in close cooperation with many leading clinicians, and based on a functioning technology platform, including the huge Mosaiques database.